Lataa...
Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
Multiple sclerosis (MS) more than any other neurological disorder has experienced a tremendous progress in available evidence-based innovator disease modifying therapies (DMT). These medications include injectable complex nonbiological drugs (CNBD), the injectable biological products β-interferons-1...
Tallennettuna:
| Julkaisussa: | Neurol Ther |
|---|---|
| Päätekijä: | |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer Healthcare
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6858917/ https://ncbi.nlm.nih.gov/pubmed/31313222 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40120-019-0145-0 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|